Atlas Venture Advisors’s Larimar Therapeutics LRMR Stock Holding History

Atlas Venture Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-112,184	Closed	-$735K	–	5
2024 Q3	$735K	Sell	112,184 -60,000	-35%	-$482K	0.15%	5
2024 Q2	$1.25M	Sell	172,184 -60,000	-26%	-$460K	0.27%	5
2024 Q1	$1.76M	Sell	232,184 -60,000	-21%	-$468K	0.35%	5
2023 Q4	$1.33M	Hold	292,184	–	–	0.23%	5
2023 Q3	$1.15M	Hold	292,184	–	–	0.25%	5
2023 Q2	$915K	Hold	292,184	–	–	0.15%	5
2023 Q1	$1.32M	Hold	292,184	–	–	0.29%	6
2022 Q4	$1.21M	Hold	292,184	–	–	0.42%	7
2022 Q3	$935K	Hold	292,184	–	–	0.34%	7
2022 Q2	$573K	Hold	292,184	–	–	0.18%	7
2022 Q1	$1.18M	Hold	292,184	–	–	0.25%	7
2021 Q4	$3.15M	Hold	292,184	–	–	0.44%	6
2021 Q3	$3.37M	Hold	292,184	–	–	0.4%	8
2021 Q2	$2.87M	Hold	292,184	–	–	0.3%	9
2021 Q1	$4.27M	Hold	292,184	–	–	0.79%	7
2020 Q4	$6.26M	Hold	292,184	–	–	1.4%	6
2020 Q3	$4.43M	Hold	292,184	–	–	0.75%	7
2020 Q2	$3.75M	Hold	292,184	–	–	0.96%	7
2020 Q1	$2.7M	Hold	292,184	–	–	3.66%	6
2019 Q4	$3.89M	Hold	292,184	–	–	5.88%	6
2019 Q3	$2.59M	Hold	292,184	–	–	0.8%	6
2019 Q2	$4.17M	Hold	292,184	–	–	1.73%	5
2019 Q1	$9.61M	Hold	292,184	–	–	4.85%	3
2018 Q4	$17.4M	Buy	+292,184	New	+$28.8M	9.16%	3

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Atlas Venture Advisors's LRMR Position: Q4 2024 in Review

Atlas Venture Advisors sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 112,184 shares — an estimated $735K sold.

Atlas Venture Advisors first reported a position in LRMR in Q4 2018 and held it in 24 quarters. The position peaked at $17.4M in Q4 2018. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

Atlas Venture Advisors reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
Atlas Venture Advisors sold 112,184 Larimar Therapeutics shares in Q4 2024, an estimated $735K.
Atlas Venture Advisors first reported a position in Larimar Therapeutics in Q4 2018 and held it in 24 quarters.
Atlas Venture Advisors's Larimar Therapeutics position peaked at $17.4M in Q4 2018.
116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on Atlas Venture Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.